Key facts
- This page summarizes Steven R. Pacelli's Form 4 filing for DEXCOM INC (DXCM).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 27 Nov 2023, 16:00.
Steven R. Pacelli - 24 Nov 2023 Form 4 Insider Report for DEXCOM INC (DXCM)
- Reporting relationship
- EVP Managing Director Dexcom V
- Issuer ticker
- DXCM
- Reported as of
- 24 Nov 2023
- Net transaction value
- -$45,539
- SEC form
- 4
- Accepted by SEC
- 27 Nov 2023, 16:00:11 UTC
- Prior SEC filing
- 23 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- By: Jereme Sylvain For: Steven R Pacelli
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Steven R. Pacelli filed Form 4 for DEXCOM INC (DXCM) on 27 Nov 2023.
Change
- Previous filing in this sequence was filed on 23 Oct 2023.
- Current net transaction value: -$45,539.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DXCM
transaction
Common Stock
Sale
- Transaction value
- $45,539
- Shares
- -411
- Change %
- -0.33%
- Price
- $110.80
- Shares after
- 124,775
- Date
- 24 Nov 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On September 15, 2022, Mr. Pacelli adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Pacelli. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.
Footnote F2
Included in this number are 39,132 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.